Market Research Logo

Hypoparathyroidism - Pipeline Review, H2 2018

Hypoparathyroidism - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoparathyroidism - Pipeline Review, H2 2018, provides an overview of the Hypoparathyroi


Introduction
Global Markets Direct Report Coverage
Hypoparathyroidism - Overview
Hypoparathyroidism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hypoparathyroidism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypoparathyroidism - Companies Involved in Therapeutics Development
Ascendis Pharma A/S
Chugai Pharmaceutical Co Ltd
Eli Lilly and Co
Entera Bio Ltd
GC Pharma
Shire Plc
Hypoparathyroidism - Drug Profiles
ACP-014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EB-612 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-607 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-6272K - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
parathyroid hormone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PCO-371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize PTHR1 for Hypoparathyroidism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem cell Therapy for Hypoparathyroidism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hypoparathyroidism - Dormant Projects
Hypoparathyroidism - Product Development Milestones
Featured News & Press Releases
Jun 06, 2018: Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon PTH as Treatment for Hypoparathyroidism
May 22, 2018: Shire Announces New Hypoparathyroidism Data at the 2018 European Congress of Endocrinology
May 07, 2018: Ascendis Pharma Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of Endocrinology
Apr 09, 2018: Shire’s Natpar Rejects For Use Within NHS Scotland
Mar 20, 2018: New Data Presented at the Endocrine Society’s 2018 Annual Meeting Advances Understanding of the Rare Disease Chronic Hypoparathyroidism
Mar 19, 2018: Ascendis Pharma Announces Posters on Rare Disease Pipeline Programs at ENDO 2018
Mar 12, 2018: Shire to Highlight Advancements in Chronic Hypoparathyroidism Research at the Endocrine Society’s 2018 Annual Meeting
Jan 08, 2018: Ascendis Pharma Provides Update on Rare Disease Endocrinology Pipeline and Presents Initial Phase 1 Data for TransCon PTH
Sep 26, 2017: Ascendis Pharma Announces Dosing of Subjects in Phase 1 Trial of TransCon PTH
Sep 15, 2017: Extend Biosciences Is Awarded A Phase II SBIR Grant From NIDDK
Sep 05, 2017: Ascendis Pharma Announces Presentations on TransCon PTH at Upcoming Medical Conferences
May 19, 2017: Shire to highlight new research into chronic hypoparathyroidism at the European Congress of Endocrinology
Apr 26, 2017: Shire Granted EU Conditional Marketing Authorization for Natpar (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism
Apr 03, 2017: Ascendis Pharma Presents Data on TransCon PTH at ENDO 2017
Feb 28, 2017: Ascendis Pharma Announces Data on TransCon PTH at ENDO 2017
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hypoparathyroidism, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Hypoparathyroidism - Pipeline by Ascendis Pharma A/S, H2 2018
Hypoparathyroidism - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018
Hypoparathyroidism - Pipeline by Eli Lilly and Co, H2 2018
Hypoparathyroidism - Pipeline by Entera Bio Ltd, H2 2018
Hypoparathyroidism - Pipeline by GC Pharma, H2 2018
Hypoparathyroidism - Pipeline by Shire Plc, H2 2018
Hypoparathyroidism - Dormant Projects, H2 2018
List of Figures
Number of Products under Development for Hypoparathyroidism, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report